Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

69.05 -4.57 (-6.21%)
Streaming Delayed Price Updated: 2:39 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,293,304
Open 73.88
Bid (Size) 68.97 (200)
Ask (Size) 69.05 (600)
Prev. Close 73.62
Today's Range 68.34 - 73.88
52wk Range 6.480 - 75.67
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks

Performance

YTD
+59.0%
+59.0%
1 Month
+85.7%
+85.7%
3 Month
+17.8%
+17.8%
6 Month
+154.4%
+154.4%
1 Year
+444.8%
+444.8%

More News

Read More
News headline image
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts ↗
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
Via The Motley Fool
Topics Bankruptcy
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher ↗
Via Chartmill
News headline image
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street ↗
Via The Motley Fool
News headline image
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗
Via The Motley Fool
News headline image
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today ↗
Via The Motley Fool
News headline image
Why Is Nektar Therapeutics Stock Trading Lower On Thursday? ↗
Via Benzinga
News headline image
Why Nektar Therapeutics Rippled Higher This Week ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?
Yes, Nektar Therapeutics - Common Stock is publicly traded.
What exchange does Nektar Therapeutics - Common Stock trade on?
Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nektar Therapeutics - Common Stock?
The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
What is the current price of Nektar Therapeutics - Common Stock?
The current price of Nektar Therapeutics - Common Stock is 69.05
When was Nektar Therapeutics - Common Stock last traded?
The last trade of Nektar Therapeutics - Common Stock was at 02/24/26 02:39 PM ET
What is the market capitalization of Nektar Therapeutics - Common Stock?
The market capitalization of Nektar Therapeutics - Common Stock is 12.69B
How many shares of Nektar Therapeutics - Common Stock are outstanding?
Nektar Therapeutics - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.